Want to see VCNX full AI Analyst Report?
VCNX Stock Chart & Stats
$1.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.31 - $1.50
Previous CloseN/A
Volume2.00
Average Volume (3M)597.00
Market Cap
$2.20M
Enterprise Value$1.65T
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume451
30 Day Avg. Volume597
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.45
Enterprise Value/Market Cap750.46K
Enterprise Value/Revenue2.74M
Enterprise Value/Gross Profit2.87M
Enterprise Value/Ebitda-89.04K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationThe sharp 2025 revenue increase shows that Vaccinex generated materially greater funding or collaboration-related activity than in the prior year. If this higher level can be sustained through additional development progress or partnerships, it could improve operating leverage and broaden future financing options.
High Gross MarginsVery high gross margins indicate that revenue, where available, has attractive economics before operating expenses. This provides a potentially favorable foundation for future profitability if Vaccinex can expand recurring or milestone-based revenue enough to absorb research, development, and corporate costs.
Proprietary Antibody PlatformA proprietary antibody platform and a lead clinical program give Vaccinex identifiable scientific assets around which it can pursue multiple therapeutic opportunities. Progress in more than one disease area may create additional partnering pathways and reduce reliance on a single indication.
Bears Say
Persistent UnprofitabilityPersistent net losses show that current revenue and gross profit are insufficient to cover operating costs, leaving the business dependent on external funding or collaboration proceeds. Continued losses could limit investment in the pipeline and make future capital raising more difficult or dilutive.
Ongoing Cash BurnNegative operating and free cash flow means Vaccinex is not yet financing development from internally generated funds. Although operating cash burn improved from 2024, continued outflows create recurring funding requirements and increase the risk that development plans depend on uncertain future financing.
Weak Balance SheetNegative equity and debt that exceeds reported assets indicate substantial financial strain and limited balance-sheet flexibility. Higher leverage can constrain capital allocation, increase refinancing pressure, and reduce the company’s ability to absorb further losses while advancing clinical programs.
Vaccinex News
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.31 and its highest was $1.50 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $2.20M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Nov 16, 2026 which is in 21 days.
How were Vaccinex Inc’s earnings last quarter?
Vaccinex Inc released its earnings results on Mar 18, 2025. The company reported -$1.26 earnings per share for the quarter.
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Vaccinex Inc reported an EPS of -$1.26 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaccinex Inc
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
6.13% Other Institutional Investors
93.87% Public Companies and
Individual Investors